Fulgent bought CSI Laboratories, a company focused on cancer diagnostic testing for pathologists, community hospitals and patients. CSI has more than 400 unique tests and capabilities in flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization, immunohistochemistry and molecular genetics.
The acquisition will expand Fulgent’s reach past its current market in Southeastern states. Larry Weiss, MD, Fulgent’s chief medical officer, will oversee the integration of CSI’s capabilities into the Fulgent platform and company operations.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
